Mylan, Fujifilm score EU thumbs-up for Humira biosimilar, putting more pressure on AbbVie

AbbVie and its investors have been fretting over the potential impact of biosimilar competition to Humira—the world’s top-selling drug, with more than $18 billion a year in sales—and now they have another contender to worry about.